Insider · CIK 0001878732
George A. Samuel III
Files at LCTX (Lineage Cell Therapeutics, Inc.). First filing Nov 26, 2024, latest Nov 26, 2024.
In brief
George A. Samuel III files SEC Form 4 as officer at LCTX (Lineage Cell Therapeutics, Inc.). Since Nov 26, 2024, George A. Samuel III has reported 1 open-market buy worth $9,000 and 0 open-market sells worth $0, the latest filed on Nov 26, 2024.
A track record needs three past buys with six months of prices behind them; George A. Samuel III has 0, so none is measured yet.
The newest scored trade: bought $9,000 of LCTX on Nov 26, 2024, filed Nov 26, 2024, scored 40 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LCTX: Lineage Cell Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Lineage Cell Therapeutics, Inc. | $9,000 15,000 shares | +209% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Mar 6, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Common Shares | +6,075 | - | - | 33,565 | Feb 13, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares | -2,502 | $1.80 | $4,504 | 31,063 | Feb 13, 2026 |
| Feb 11, 2026 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -6,075 | $0.00 | $0 | 0 | Feb 13, 2026 |
| Dec 19, 2025 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Common Shares | +1,735 | - | - | 27,555 | Dec 19, 2025 |
| Dec 19, 2025 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares | -65 | $1.68 | $109 | 27,490 | Dec 19, 2025 |
| Nov 26, 2024 | LCTX Lineage Cell Therapeutics, Inc. | POpen-market purchase Common Shares | +15,000 | $0.60 | $9,000 | 22,184 | Nov 26, 2024 |
| Mar 7, 2024 | LCTX Lineage Cell Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Mar 8, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Common Shares, no par value | +6,076 | - | - | 9,674 | Feb 12, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | FTax withholding Common Shares, no par value | -2,490 | $1.08 | $2,689 | 7,184 | Feb 12, 2024 |
| Feb 11, 2024 | LCTX Lineage Cell Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -6,076 | $0.00 | $0 | 12,151 | Feb 12, 2024 |
Questions about George A. Samuel III
Answered from the filings on this page, as of the latest one.
Is George A. Samuel III buying or selling?
Not in the last 12 months. George A. Samuel III's latest open-market trade on SEC Form 4 was bought $9,000 of LCTX on Nov 26, 2024.
How did George A. Samuel III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and George A. Samuel III has 0.
Where does George A. Samuel III file Form 4?
George A. Samuel III has filed Form 4 at LCTX (Lineage Cell Therapeutics, Inc.) as General Counsel/Secretary. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.